Slide 1: Strategy execution in 2022, Business update, Financial performance, Outlook 2023
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices
Slide 2: Q4 and Full Year 2022 Results: Play to Win
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Q4 and Full Year 2022 Results Play to Win February 3, 2023
Slide 3: Forward-looking statements
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that are no
Slide 4: Agenda
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Agenda 01 Strategy execution delivered strong growth in 2022 Paul Hudson 02 Business update Bill Sibold, Thomas Triomphe, Olivier Charmeil & Julie Van Ongevalle 03 Financial performance and outlook 2023 Jean-Bap
Slide 5: Strategy execution delivered strong growth in 2022
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Strategy execution delivered strong growth in 2022
Slide 6: FY 2022 performance
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices FY 2022 performance Specialty Care Vaccines GenMed Company sales growth €16.5bn €7.2bn €14.2bn €43.0bn +19.4% +6.3% -4.2% +7.0% Core assets 2020 2021 2022 €6.4bn +5.2% Business EPS growth Consumer Healthcare €8.
Slide 7: Strategic transformation delivered first set of guidance targets
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Strategic transformation delivered first set of guidance targets 2020 - 2022 10 consecutive quarters of growth 540bps BOI margin improvement EPS growth BOI margin ~16% from 2019 to 20221 €2.7bn cost savings re-i
Slide 8: Driving innovation to significantly improve patients' lives
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Driving innovation to significantly improve patients’ lives 9 Major publications 2022 5 Priority reviews/ accelerated assessment Infant AD | EoE | PN Breakthrough Therapy Designation EMA accelerated assessment 2
Slide 9: Acoziborole: Strong commitment to eliminate sleeping sickness
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Acoziborole: Strong commitment to eliminate sleeping sickness Number of sleeping sickness cases diagnosed Acoziborole 95% 40000 Partnership Investigational single dose Sanofi/WHO treatment “test and treat” preve
Slide 10: Powerful business and pipeline momentum into 2023
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Powerful business and pipeline momentum into 2023 Pivotal Early to Launches readouts mid-stage pipeline 27 readouts Expansion into COPD in immunology, tolebrutinib (BTKi) vaccines, neurology, Relapsing MS rare d
Slide 11: Play to Win: Leverage innovation to drive next growth chapter
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Play to Win: Leverage innovation to drive next growth chapter Toda y 2020-2022 2023-2025 2026-2030 Refocus with Transformative Industry leader in immunology decisive actions launches with >€22bn sales by 2030 Gu
Slide 12: Q4 2022 performance
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Q4 2022 performance Specialty Care Vaccines GenMed Specialty Care Continued strong performance €4.4bn €1.7bn €3.4bn of Dupixent® +18.1% -16.3% -3.7% Core assets Vaccines Phasing effect in flu and €1.6bn PPH, con
Slide 13: Business update Q4 2022
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Business update Q4 2022
Slide 14: Specialty Care performance €4.4bn sales
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Specialty Care performance €4.4bn sales +18.1% Q4 2022 Rare Diseases Dupixent® Dupixent® Outstanding performance, adding 225K biologics €850m €2,402m eligible p
Slide 15: Dupixent – Reaching €10bn in 2023
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Dupixent – Reaching €10bn in 2023 ® Global Dupixent® sales (€m) Performance highlights in Q4 +3,044 Ex-U.S. Worldwide Ex-U.S. annualizing U.S. 8,293 growth of +
Slide 16: Dupixent – Leading respiratory biologic in the U.S.
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Dupixent – Leading respiratory biologic in the U.S. ® U.S. Respiratory Biologic 4Q-22 NBRx Share1 Dupixent® drives growth of underpenetrated asthma biologics ma
Slide 17: Launch execution secures leadership in Rare Diseases
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Launch execution secures leadership in Rare Diseases Q4 launch highlights First and only therapy indicated ~30% of identified for the treatment of ASMD patients
Slide 18: Committed to set a new standard for bleed protection in Hemophilia A
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Committed to set a new standard for bleed protection in Hemophilia A Significant bleed protection with the convenience of a weekly dosing regimen1 Only factor r
Slide 19: Vaccines performance €1.7bn sales
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Vaccines performance €1.7bn sales -16.3% Q4 2022 Q4 performance reflecting anticipated Travel & Endemic Meningitis sales phasing in flu and PPH €121m €110m +28.
Slide 20: Protection Beyond Flu strategy delivers record results
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Protection Beyond Flu strategy delivers record results Continued success of our flu strategy Strong growth for vaccines providing €1,781m despite low vaccinatio
Slide 21: Increasing momentum in pediatric immunization
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Increasing momentum in pediatric immunization Solid U.S. Vaxelis® adoption since launch 26% 23% Ready to launch Beyfortus® to provide 20% protection for a broad
Slide 22: GenMed performance €3.4bn sales
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare GenMed performance €3.4bn sales -3.7% Q4 2022 Core assets on track Core assets Non-core assets Robust growth of Rezurock®, Praluent® and Toujeo® €1,598m €1,604m
Slide 23: GenMed 2022 performance supports objective of 60% core asset sales
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare GenMed 2022 performance supports strategic objective of reaching 60% core asset sales Core asset sales (in € million) GenMed sales (excl. IA sales) -13.8% 1,486
Slide 24: CHC: Strong market growth
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare CHC: Strong market growth Growth (MAT, in %) Recent market growth trends driven by Cough & Cold, particularly in the U.S. +16.5% +15.4% +15.5% +13.6% +12.9% San
Slide 25: CHC performance €1.2bn sales
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare CHC performance €1.2bn sales +6.6% Q4 2022 Cough & Cold Allergy Q4 organic growth +7.5% €132m €156m +11.2% +15.0% 7th consecutive growth quarter Digestive Welln
Slide 26: Standout performance for our regional and local brands
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Standout performance for our regional and local brands #1 #1 Cough Effie award for General Pain Don’t Hide the Cough Japan Europe campaign Source: Dec MAT, Anal
Slide 27: Financial performance 2022
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Financial performance 2022
Slide 28: Double-digit EPS growth driven by sales and margin expansion
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Double-digit EPS growth driven by sales and margin expansion €m FY 2022 FY 2021 % Change Net Sales 42,997 37,761 +7.0% Sales growth +7.0% Other revenues 2,392 1,414 +51.9% Gross profit 31,697 26,924 +9.7% Gross
Slide 29: New operating segment profit reporting as of Q1 2023
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices New operating segment profit reporting as of Q1 2023 Efficiency gains from Biopharma Consumer Healthcare merged Pharma and Vaccines manufacturing and supply Combining manufacturing CHC standalone now moving and
Slide 30: Taking bolder steps towards our net zero ambition
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Taking bolder steps towards our net zero ambition FY 2022 2030 2045 Carbon neutrality -29% scope 1&2 -7% scope 3 -55% -30% Net zero emissions scope 1&2 scope 3 62% renewable electricity 100% renewable electricit
Slide 31: Proposed dividend of €3.56
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Proposed dividend of €3.56 1993 2022 Subject to AGM’s approval on May 25, 2023. 31 Investor Relations
Slide 32: Outlook 2023
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Outlook 2023
Slide 33: 2023 FY guidance
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices 2023 FY guidance EPS growth Currency impact 1 Low single-digit approximately growth at CER -3.5% to -4.5% Barring unforeseen events. 1. Based on January 2023 average rates. 33 Investor Relations
Slide 34: Q&A session
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices Q&A session
Slide 35: R&D appendices
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D appendices
Slide 36: Upcoming newsflow over the next 15 months
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Upcoming newsflow over the next 15 months 9 Phase 3/pivotal readouts 27 Phase 1-2 readouts SAR442257 MM / N-H Lymphoma tusamitamab
Slide 37: R&D Pipeline Phase III & Registration
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline Phase III & Registration Phase III Registration Name Description Indication Name Description Indication Dupixent®A Ant
Slide 38: R&D Pipeline – Phase II
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline – Phase II Phase II Name Description Indication Name Description Indication Polyarticular Juvenile Idiopathic SAR44508
Slide 39: R&D Pipeline – Phase I
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline – Phase I Phase I Name Description Indication SAR441566 Oral TNF inhibitor Inflammatory indication SAR444656G,1 IRAK4
Slide 40: Expected major R&D milestones in 2023
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Expected major R&D milestones in 2023 H1 2023 H2 2023 COPD Pivotal trial readout (BOREAS) Dupixent® CIndU Pivotal trial readout Sar
Slide 41: Expected submission timelines
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Expected submission timelines 2023 2024 2025 and beyond Kevzara®A ®A Nexviazyme® Dupixent®A Sarclisa® SubQ Dupixent®A Dupixent Poly
Slide 42: R&D innovation in 2022
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D innovation in 2022 Feb 2022 Mar 2022 Mar 2022 Apr 2022 Survival with Cemiplimab in Nirsevimab for Prevention of Safety of Nirse
Slide 43: Financial appendices
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Financial appendices
Slide 44: Q4 P&L
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Q4 P&L €m Q4 2022 Q4 2021 % Change (CER) Net Sales 10,725 9,994 +2.6% Other revenues 731 421 +58.2% Gross profit 7,722 6,944 +5.4%
Slide 45: Q4 sales and EPS
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Q4 sales and EPS Currency impact Company sales Business EPS €1,108m +0.31 €661m +0.09 €341m +0.12 €225m €475m +0.07 0 +0.04 -0.11 0
Slide 46: Net debt evolution in 2022
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Net debt evolution in 2022 € millions 9,983 -8,902 6,437 4,168 -423 1,126 2,016 -1,531 Net Debt FCF before Proceeds Asset Restructu
Slide 47: 2023 currency sensitivity and Q4 2022 currency exposure
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations 2023 currency sensitivity and Q4 2022 currency exposure 2023 Business EPS currency sensitivity Currency exposure on Q4 2022 sales C
Slide 48: Main product sales
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Main product sales 2022 sales (€m) Growth Dupixent 8,293 43.8% Influenza Vaccines 2,977 2.4% Lantus 2,259 -14.4% Aubagio 2,031 -4.3
Slide 49: Sanofi accounting of nirsevimab/Beyfortus (from 2023)
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi accounting of nirsevimab/Beyfortus® (from 2023) Agreement with AstraZeneca Last updated January 2023 Major markets (U.S., FR
Slide 50: ESG appendices
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations ESG appendices
Slide 51: Sanofi ESG Q4 achievements
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG Q4 achievements Affordable access R&D for unmet needs Global Health Unit #Patients treated Rare disease vials donation P
Slide 52: Sanofi ESG Q4 achievements
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG Q4 achievements Planet care In and beyond the workplace Blister-free syringe vaccines Scope 1 & 2 Diverse Senior Engagem
Slide 53: Sanofi ESG ratings
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG ratings Rating agencies SCORE Climate 21.2 86/100 70/100 A Change: A B 4.3/5 3.47/5 64/100 Medium risk Water: A- New rat
Slide 54: Collaborations
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Collaborations Ref Name Developed in collaboration with… A Dupixent® Regeneron itepekimab Kevzara® B Altuviiio™ Sobi C Beyfortus® A
Slide 55: Abbreviations
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Abbreviations Ab Antibody GPC3 Glypican-3 PCV Pneumococcal Conjugate Vaccine AD Atopic Dermatitis HD High Dose PD-1 Programmed cell
Slide 56: Strategy execution in 2022 Business update Financial performance
Strategy execution in 2022 Business update Financial performance Outlook 2023 Appendices